Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report

Cancer Genetics and Cytogenetics

Volumn 195, Issue 1, 2009, Pages 75-79

  Papi, Laura ^a   Palli, Domenico ^b   Masi, Laura ^c   Putignano, Anna Laura ^a   Congregati, Caterina ^a   Zanna, Ines ^b   Marini, Francesca ^c   Giusti, Francesca ^c   Luzi, Ettore ^c   Tonelli, Francesco ^a   Genuardi, Maurizio ^a   Brandi, Maria Luisa ^c,d   Falchetti, Alberto ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^c Unit of Metabolic Bone Diseases   (Italy)

^d Spin off DeGene   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; GENE PRODUCT; MULTIPLE ENDOCRINE NEOPLASIA 1 PROTEIN; UNCLASSIFIED DRUG;

ABDOMINAL TUMOR; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; INHERITED BREAST OVARY CANCER SYNDROME; INSULINOMA; LIPOMA; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; PEDIGREE ANALYSIS; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GERM-LINE MUTATION; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS;

EID: 70349863384     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.06.019     Document Type: Article

References (19)

1. Larsson C., Skogseid B., Oberg K., Nakamura Y., and Nordenskjöld M. Multiple endocrine neoplasia type I gene maps to chromosome 11 and is lost in insulinoma. Nature 332 (1988) 85-87
2. Chandrasekharappa S.C., Guru S.C., Manickam P., Olufemi S.E., Collins F.S., Emmert-Buck M.R., Debelenko L.V., Zhuang Z., Lubensky I.A., Liotta L.A., Crabtree J.S., Wang Y., Roe B.A., Weisemann J., Boguski M.S., Agarwal S.K., Kester M.B., Kim Y.S., Heppner C., Dong Q., Spiegel A.M., Burns A.L., and Marx S.J. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 (1997) 404-407
3. Brandi M.L., Gagel R.F., Angeli A., Bilezikian J.P., Beck-Peccoz P., Bordi C., Conte-Devolx B., Falchetti A., Gheri R.G., Libroia A., Lips C.J., Lombardi G., Mannelli M., Pacini F., Ponder B.A., Raue F., Skogseid B., Tamburrano G., Thakker R.V., Thompson N.W., Tomassetti P., Tonelli F., Wells Jr. S.A., and Marx S.J. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 (2001) 5658-5671
4. Falchetti A, Marini F, Brandi ML. Multiple Endocrine Neoplasia Type 1. In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Available at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=men1. Posted August 31, 2005.
5. Gibril F., Chen Y.J., Schrump D.S., Vortmeyer A., Zhuang Z., Lubensky I.A., Reynolds J.C., Louie A., Entsuah L.K., Huang K., Asgharian B., and Jensen R.T. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 88 (2003) 1066-1081
6. Brose M.S., Rebbeck T.R., Calzone K.A., Stopfer J.E., Nathanson K.L., and Weber B.L. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94 (2002) 1365-1372
7. King M.C., Marks J.H., and Mandell J.B. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
8. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., Loman N., Olsson H., Johannsson O., Borg A., Pasini B., Radice P., Manoukian S., Eccles D.M., Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B., Tulinius H., Thorlacius S., Eerola H., Nevanlinna H., Syrjäkoski K., Kallioniemi O.P., Thompson D., Evans C., Peto J., Lalloo F., Evans D.G., and Easton D.F. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies [Erratum in: Am J Hum Genet 2003;73:709]. Am J Hum Genet 72 (2003) 1117-1130
9. Ghataorhe P., Kurian A.W., Pickart A., Trapane P., Norton J.A., Kingham K., and Ford J.M. A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. Cancer Genet Cytogenet 179 (2007) 89-92
10. Tonelli F., Marcucci T., Fratini G., Tommasi M.S., Falchetti A., and Brandi M.L. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1?. Ann Surg 246 (2007) 1075-1082
11. Papi L., Putignano A.L., Congregati C., Zanna I., Sera F., Morrone D., Falchetti M., Turco M.R., Ottini L., Palli D., and Genuardi M. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. Breast Cancer Res Treat (2008 Sep 27) [Epub ahead of print]
12. Honda M., Tsukada T., Horiuchi T., Tanaka R., Yamaguchi K., Obara T., Miyakawa H., Yamaji T., and Ishibashi M. Primary hyperparathyroidism associated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. Intern Med 43 (2004) 310-314
13. Dreijerink K.M., Mulder K.W., Winkler G.S., Höppener J.W., Lips C.J., and Timmers H.T. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res 66 (2006) 4929-4935
14. Fan S., Yuan R., Ma Y.X., Meng Q., Goldberg I.D., and Rosen E.M. Mutant BRCA1 genes antagonize phenotype of wild type BRCA1. Oncogene 20 (2001) 8215-8235
15. Kawai H., Li H., Chun P., Avraham S., and Avraham H.K. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21 (2002) 7730-7739
16. Zheng L., Annab L.A., Afshari C.A., Lee W.H., and Boyer T.G. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A 98 (2001) 9587-9592
17. Howell A., Bundred N.J., Cuzick J., Allred D.C., and Clarke R. Response and resistance to the endocrine prevention of breast cancer. Adv Exp Med Biol 617 (2008) 201-211
18. Ganz P.A., and Land S.R. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer. Menopause 15 (2008) 797-803
19. Vogel V.G. Preventing breast cancer in high-risk women, 2008. Oncology (Williston Park) 22 (2008) 666-673